text:
Gene therapy
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Gene therapy using an adenovirus vector. In some cases, the adenovirus will insert the new gene into a cell. If the treatment is successful, the new gene will make a functional protein to treat a disease.
In medicine, gene therapy (also called human gene transfer) is the therapeutic delivery of nucleic acid into a patient's cells as a drug to treat disease.[1] The first attempt at modifying human DNA was performed in 1980 by Martin Cline, but the first successful nuclear gene transfer in humans, approved by the National Institutes of Health, was performed in May 1989.[2] The first therapeutic use of gene transfer as well as the first direct insertion of human DNA into the nuclear genome was performed by French Anderson in a trial starting in September 1990.
Between 1989 and February 2016, over 2,300 clinical trials had been conducted, more than half of them in phase I.[3]
Not all medical procedures that introduce alterations to a patient's genetic makeup can be considered gene therapy. Bone marrow transplantation and organ transplants in general have been found to introduce foreign DNA into patients.[4] Gene therapy is defined by the precision of the procedure and the intention of direct therapeutic effects.
Contents
[hide]
1 Background
2 Approaches
3 Cell types
3.1 Somatic
3.2 Germline
4 Vectors
4.1 Viruses
4.2 Non-viral
5 Hurdles
5.1 Deaths
6 History
6.1 1970s and earlier
6.2 1980s
6.3 1990s
6.4 2000s
6.4.1 2002
6.4.2 2003
6.4.3 2006
6.4.4 2007
6.4.5 2008
6.4.6 2009
6.5 2010s
6.5.1 2010
6.5.2 2011
6.5.3 2012
6.5.4 2013
6.5.5 2014
6.5.6 2015
6.5.7 2016
6.5.8 2017
7 Speculative uses
7.1 Fertility
7.2 Gene doping
7.3 Human genetic engineering
8 Regulations
8.1 United States
9 Popular culture
10 See also
11 References
12 Further reading
13 External links
Background[edit]
Gene therapy was conceptualized in 1972, by authors who urged caution before commencing human gene therapy studies.
The first attempt, an unsuccessful one, at gene therapy (as well as the first case of medical transfer of foreign genes into humans not counting organ transplantation) was performed by Martin Cline on 10 July 1980.[5][6] Cline claimed that one of the genes in his patients was active six months later, though he never published this data or had it verified[7] and even if he is correct, it's unlikely it produced any significant beneficial effects treating beta-thalassemia.
After extensive research on animals throughout the 1980s and a 1989 bacterial gene tagging trial on humans, the first gene therapy widely accepted as a success was demonstrated in a trial that started on 14 September 1990, when Ashi DeSilva was treated for ADA-SCID.[8]
The first somatic treatment that produced a permanent genetic change was performed in 1993.[citation needed]
This procedure was referred to sensationally and somewhat inaccurately in the media as a "three parent baby", though mtDNA is not the primary human genome and has little effect on an organism's individual characteristics beyond powering their cells.
Gene therapy is a way to fix a genetic problem at its source. The polymers are either translated into proteins, interfere with target gene expression, or possibly correct genetic mutations.
The most common form uses DNA that encodes a functional, therapeutic gene to replace a mutated gene. The polymer molecule is packaged within a "vector", which carries the molecule inside cells.
Early clinical failures led to dismissals of gene therapy. Clinical successes since 2006 regained researchers' attention, although as of 2014, it was still largely an experimental technique.[9] These include treatment of retinal diseases Leber's congenital amaurosis[10][11][12][13] and choroideremia,[14] X-linked SCID,[15] ADA-SCID,[16][17] adrenoleukodystrophy,[18] chronic lymphocytic leukemia (CLL),[19] acute lymphocytic leukemia (ALL),[20] multiple myeloma,[21] haemophilia,[17] and Parkinson's disease.[22] Between 2013 and April 2014, US companies invested over $600 million in the field.[23]
The first commercial gene therapy, Gendicine, was approved in China in 2003 for the treatment of certain cancers.[24] In 2011 Neovasculgen was registered in Russia as the first-in-class gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia.[25] In 2012 Glybera, a treatment for a rare inherited disorder, became the first treatment to be approved for clinical use in either Europe or the United States after its endorsement by the European Commission.[9][26]
Approaches[edit]
Following early advances in genetic engineering of bacteria, cells, and small animals, scientists started considering how to apply it to medicine. Two main approaches were considered – replacing or disrupting defective genes.[27] Scientists focused on diseases caused by single-gene defects, such as cystic fibrosis, haemophilia, muscular dystrophy, thalassemia, and sickle cell anemia. Glybera treats one such disease, caused by a defect in lipoprotein lipase.[26]
DNA must be administered, reach the damaged cells, enter the cell and either express or disrupt a protein.[28] Multiple delivery techniques have been explored. The initial approach incorporated DNA into an engineered virus to deliver the DNA into a chromosome.[29][30] Naked DNA approaches have also been explored, especially in the context of vaccine development.[31]
Generally, efforts focused on administering a gene that causes a needed protein to be expressed. More recently, increased understanding of nuclease function has led to more direct DNA editing, using techniques such as zinc finger nucleases and CRISPR. The vector incorporates genes into chromosomes. The expressed nucleases then knock out and replace genes in the chromosome. As of 2014 these approaches involve removing cells from patients, editing a chromosome and returning the transformed cells to patients.[32]
Gene editing is a potential approach to alter the human genome to treat genetic diseases,[33] viral diseases,[34] and cancer.[35] As of 2016 these approaches were still years from being medicine.[36][37]
A duplex of crRNA and tracrRNA acts as guide RNA to introduce a specifically located gene modification based on the RNA 5’ upstream of the crRNA. Cas9 binds the tracrRNA and needs a DNA binding sequence (5’NGG3’), which is called protospacer adjacent motif (PAM). After binding, Cas9 introduces a DNA double strand break, which is then followed by gene modification via homologous recombination (HDR) or non-homologous end joining (NHEJ).
Cell types[edit]
Gene therapy may be classified into two types:
Somatic[edit]
In somatic cell gene therapy (SCGT), the therapeutic genes are transferred into any cell other than a gamete, germ cell, gametocyte, or undifferentiated stem cell. Any such modifications affect the individual patient only, and are not inherited by offspring. Somatic gene therapy represents mainstream basic and clinical research, in which therapeutic DNA (either integrated in the genome or as an external episome or plasmid) is used to treat disease.
Over 600 clinical trials utilizing SCGT are underway in the US. Most focus on severe genetic disorders, including immunodeficiencies, haemophilia, thalassaemia, and cystic fibrosis. Such single gene disorders are good candidates for somatic cell therapy. The complete correction of a genetic disorder or the replacement of multiple genes is not yet possible. Only a few of the trials are in the advanced stages.[38]
Germline[edit]
In germline gene therapy (GGT), germ cells (sperm or egg cells) are modified by the introduction of functional genes into their genomes. Modifying a germ cell causes all the organism's cells to contain the modified gene. The change is therefore heritable and passed on to later generations. Australia, Canada, Germany, Israel, Switzerland, and the Netherlands[39] prohibit GGT for application in human beings, for technical and ethical reasons, including insufficient knowledge about possible risks to future generations[39] and higher risks versus SCGT.[40] The US has no federal controls specifically addressing human genetic modification (beyond FDA regulations for therapies in general).[39][41][42][43]
Vectors[edit]
Main article: Vectors in gene therapy
The delivery of DNA into cells can be accomplished by multiple methods. The two major classes are recombinant viruses (sometimes called biological nanoparticles or viral vectors) and naked DNA or DNA complexes (non-viral methods).
Viruses[edit]
Main article: Viral vector
In order to replicate, viruses introduce their genetic material into the host cell, tricking the host's cellular machinery into using it as blueprints for viral proteins. Retroviruses go a stage further by having their genetic material copied into the genome of the host cell. Scientists exploit this by substituting a virus's genetic material with therapeutic DNA. (The term 'DNA' may be an oversimplification, as some viruses contain RNA, and gene therapy could take this form as well.) A number of viruses have been used for human gene therapy, including retroviruses, adenoviruses, herpes simplex, vaccinia, and adeno-associated virus.[3] Like the genetic material (DNA or RNA) in viruses, therapeutic DNA can be designed to simply serve as a temporary blueprint that is degraded naturally or (at least theoretically) to enter the host's genome, becoming a permanent part of the host's DNA in infected cells.
Non-viral[edit]
Non-viral methods present certain advantages over viral methods, such as large scale production and low host immunogenicity. However, non-viral methods initially produced lower levels of transfection and gene expression, and thus lower therapeutic efficacy. Later technology remedied this deficiency[citation needed].
Methods for non-viral gene therapy include the injection of naked DNA, electroporation, the gene gun, sonoporation, magnetofection, the use of oligonucleotides, lipoplexes, dendrimers, and inorganic nanoparticles.
Hurdles[edit]
Some of the unsolved problems include:
Short-lived nature – Before gene therapy can become a permanent cure for a condition, the therapeutic DNA introduced into target cells must remain functional and the cells containing the therapeutic DNA must be stable. Problems with integrating therapeutic DNA into the genome and the rapidly dividing nature of many cells prevent it from achieving long-term benefits. Patients require multiple treatments.
Immune response – Any time a foreign object is introduced into human tissues, the immune system is stimulated to attack the invader. Stimulating the immune system in a way that reduces gene therapy effectiveness is possible. The immune system's enhanced response to viruses that it has seen before reduces the effectiveness to repeated treatments.
Problems with viral vectors – Viral vectors carry the risks of toxicity, inflammatory responses, and gene control and targeting issues.
Multigene disorders – Some commonly occurring disorders, such as heart disease, high blood pressure, Alzheimer's disease, arthritis, and diabetes, are affected by variations in multiple genes, which complicate gene therapy.
Some therapies may breach the Weismann barrier (between soma and germ-line) protecting the testes, potentially modifying the germline, falling afoul of regulations in countries that prohibit the latter practice.[44]
Insertional mutagenesis – If the DNA is integrated in a sensitive spot in the genome, for example in a tumor suppressor gene, the therapy could induce a tumor. This has occurred in clinical trials for X-linked severe combined immunodeficiency (X-SCID) patients, in which hematopoietic stem cells were transduced with a corrective transgene using a retrovirus, and this led to the development of T cell leukemia in 3 of 20 patients.[45][46] One possible solution is to add a functional tumor suppressor gene to the DNA to be integrated. This may be problematic since the longer the DNA is, the harder it is to integrate into cell genomes. CRISPR technology allows researchers to make much more precise genome changes at exact locations.[47]
Cost – Alipogene tiparvovec or Glybera, for example, at a cost of $1.6 million per patient, was reported in 2013 to be the world's most expensive drug.[48][49]
Deaths[edit]
Three patients' deaths have been reported in gene therapy trials, putting the field under close scrutiny. The first was that of Jesse Gelsinger in 1999. Jesse Gelsinger died because of immune rejection response.[50] One X-SCID patient died of leukemia in 2003.[8] In 2007, a rheumatoid arthritis patient died from an infection; the subsequent investigation concluded that the death was not related to gene therapy.[51]
History[edit]
1970s and earlier[edit]
In 1972 Friedmann and Roblin authored a paper in Science titled "Gene therapy for human genetic disease?"[52] Rogers (1970) was cited for proposing that exogenous good DNA be used to replace the defective DNA in those who suffer from genetic defects.[53]
1980s[edit]
In 1984 a retrovirus vector system was designed that could efficiently insert foreign genes into mammalian chromosomes.[54]
1990s[edit]
The first approved gene therapy clinical research in the US took place on 14 September 1990, at the National Institutes of Health (NIH), under the direction of William French Anderson.[55] Four-year-old Ashanti DeSilva received treatment for a genetic defect that left her with ADA-SCID, a severe immune system deficiency. The effects were temporary, but successful.[56]
Cancer gene therapy was introduced in 1992/93 (Trojan et al. 1993).[57] The treatment of glioblastoma multiforme, the malignant brain tumor whose outcome is always fatal, was done using a vector expressing antisense IGF-I RNA (clinical trial approved by NIH protocolno.1602 November 24, 1993,[58] and by the FDA in 1994). This therapy also represents the beginning of cancer immunogene therapy, a treatment which proves to be effective due to the anti-tumor mechanism of IGF-I antisense, which is related to strong immune and apoptotic phenomena.
In 1992 Claudio Bordignon, working at the Vita-Salute San Raffaele University, performed the first gene therapy procedure using hematopoietic stem cells as vectors to deliver genes intended to correct hereditary diseases.[59] In 2002 this work led to the publication of the first successful gene therapy treatment for adenosine deaminase deficiency (ADA-SCID). The success of a multi-center trial for treating children with SCID (severe combined immune deficiency or "bubble boy" disease) from 2000 and 2002, was questioned when two of the ten children treated at the trial's Paris center developed a leukemia-like condition. Clinical trials were halted temporarily in 2002, but resumed after regulatory review of the protocol in the US, the United Kingdom, France, Italy, and Germany.[60]
In 1993 Andrew Gobea was born with SCID following prenatal genetic screening. Blood was removed from his mother's placenta and umbilical cord immediately after birth, to acquire stem cells. The allele that codes for adenosine deaminase (ADA) was obtained and inserted into a retrovirus. Retroviruses and stem cells were mixed, after which the viruses inserted the gene into the stem cell chromosomes. Stem cells containing the working ADA gene were injected into Andrew's blood. Injections of the ADA enzyme were also given weekly. For four years T cells (white blood cells), produced by stem cells, made ADA enzymes using the ADA gene. After four years more treatment was needed.[61]
Jesse Gelsinger's death in 1999 impeded gene therapy research in the US.[62][63] As a result, the FDA suspended several clinical trials pending the reevaluation of ethical and procedural practices.[64]
2000s[edit]
The modified cancer gene therapy strategy of antisense IGF-I RNA (NIH n˚ 1602)[58] using antisense / triple helix anti IGF-I approach was registered in 2002 by Wiley gene therapy clinical trial - n˚ 635 and 636. The approach has shown promising results in the treatment of six different malignant tumors: glioblastoma, cancers of liver, colon, prostate, uterus, and ovary (Collaborative NATO Science Programme on Gene Therapy USA, France, Poland n˚ LST 980517 conducted by J. Trojan) (Trojan et al., 2012). This anti–gene antisense/triple helix therapy has proven to be efficient, due to the mechanism stopping simultaneously IGF-I expression on translation and transcription levels, strengthening anti-tumor immune and apoptotic phenomena.
2002[edit]
Sickle-cell disease can be treated in mice.[65] The mice – which have essentially the same defect that causes human cases – used a viral vector to induce production of fetal hemoglobin (HbF), which normally ceases to be produced shortly after birth. In humans, the use of hydroxyurea to stimulate the production of HbF temporarily alleviates sickle cell symptoms. The researchers demonstrated this treatment to be a more permanent means to increase therapeutic HbF production.[66]
A new gene therapy approach repaired errors in messenger RNA derived from defective genes. This technique has the potential to treat thalassaemia, cystic fibrosis and some cancers.[67]
Researchers created liposomes 25 nanometers across that can carry therapeutic DNA through pores in the nuclear membrane.[68]
2003[edit]
In 2003 a research team inserted genes into the brain for the first time. They used liposomes coated in a polymer called polyethylene glycol, which, unlike viral vectors, are small enough to cross the blood–brain barrier.[69]
Short pieces of double-stranded RNA (short, interfering RNAs or siRNAs) are used by cells to degrade RNA of a particular sequence. If a siRNA is designed to match the RNA copied from a faulty gene, then the abnormal protein product of that gene will not be produced.[70]
Gendicine is a cancer gene therapy that delivers the tumor suppressor gene p53 using an engineered adenovirus. In 2003, it was approved in China for the treatment of head and neck squamous cell carcinoma.[24]
2006[edit]
In March researchers announced the successful use of gene therapy to treat two adult patients for X-linked chronic granulomatous disease, a disease which affects myeloid cells and damages the immune system. The study is the first to show that gene therapy can treat the myeloid system.[71]
In May a team reported a way to prevent the immune system from rejecting a newly delivered gene.[72] Similar to organ transplantation, gene therapy has been plagued by this problem. The immune system normally recognizes the new gene as foreign and rejects the cells carrying it. The research utilized a newly uncovered network of genes regulated by molecules known as microRNAs. This natural function selectively obscured their therapeutic gene in immune system cells and protected it from discovery. Mice infected with the gene containing an immune-cell microRNA target sequence did not reject the gene.
In August scientists successfully treated metastatic melanoma in two patients using killer T cells genetically retargeted to attack the cancer cells.[73]
In November researchers reported on the use of VRX496, a gene-based immunotherapy for the treatment of HIV that uses a lentiviral vector to deliver an antisense gene against the HIV envelope. In a phase I clinical trial, five subjects with chronic HIV infection who had failed to respond to at least two antiretroviral regimens were treated. A single intravenous infusion of autologous CD4 T cells genetically modified with VRX496 was well tolerated. All patients had stable or decreased viral load; four of the five patients had stable or increased CD4 T cell counts. All five patients had stable or increased immune response to HIV antigens and other pathogens. This was the first evaluation of a lentiviral vector administered in a US human clinical trial.[74][75]
2007[edit]
In May researchers announced the first gene therapy trial for inherited retinal disease. The first operation was carried out on a 23-year-old British male, Robert Johnson, in early 2007.[76]
2008[edit]
Main article: Gene therapy of the human retina
Leber's congenital amaurosis is an inherited blinding disease caused by mutations in the RPE65 gene. The results of a small clinical trial in children were published in April.[10] Delivery of recombinant adeno-associated virus (AAV) carrying RPE65 yielded positive results. In May two more groups reported positive results in independent clinical trials using gene therapy to treat the condition. In all three clinical trials, patients recovered functional vision without apparent side-effects.[10][11][12][13]
2009[edit]
In September researchers were able to give trichromatic vision to squirrel monkeys.[77] In November 2009, researchers halted a fatal genetic disorder called adrenoleukodystrophy in two children using a lentivirus vector to deliver a functioning version of ABCD1, the gene that is mutated in the disorder.[78]
2010s[edit]
2010[edit]
An April paper reported that gene therapy addressed achromatopsia (color blindness) in dogs by targeting cone photoreceptors. Cone function and day vision were restored for at least 33 months in two young specimens. The therapy was less efficient for older dogs.[79]
In September it was announced that an 18-year-old male patient in France with beta-thalassemia major had been successfully treated.[80] Beta-thalassemia major is an inherited blood disease in which beta haemoglobin is missing and patients are dependent on regular lifelong blood transfusions.[81] The technique used a lentiviral vector to transduce the human ß-globin gene into purified blood and marrow cells obtained from the patient in June 2007.[82] The patient's haemoglobin levels were stable at 9 to 10 g/dL. About a third of the hemoglobin contained the form introduced by the viral vector and blood transfusions were not needed.[82][83] Further clinical trials were planned.[84] Bone marrow transplants are the only cure for thalassemia, but 75% of patients do not find a matching donor.[83]
Cancer immunogene therapy using modified anti – gene, antisense / triple helix approach was introduced in South America in 2010/11 in La Sabana University, Bogota (Ethical Committee 14 December 2010, no P-004-10). Considering the ethical aspect of gene diagnostic and gene therapy targeting IGF-I, the IGF-I expressing tumors i.e. lung and epidermis cancers, were treated (Trojan et al. 2016).[85][86]
2011[edit]
In 2007 and 2008, a man (Timothy Ray Brown) was cured of HIV by repeated hematopoietic stem cell transplantation (see also allogeneic stem cell transplantation, allogeneic bone marrow transplantation, allotransplantation) with double-delta-32 mutation which disables the CCR5 receptor. This cure was accepted by the medical community in 2011.[87] It required complete ablation of existing bone marrow, which is very debilitating.
In August two of three subjects of a pilot study were confirmed to have been cured from chronic lymphocytic leukemia (CLL). The therapy used genetically modified T cells to attack cells that expressed the CD19 protein to fight the disease.[19] In 2013, the researchers announced that 26 of 59 patients had achieved complete remission and the original patient had remained tumor-free.[88]
Human HGF plasmid DNA therapy of cardiomyocytes is being examined as a potential treatment for coronary artery disease as well as treatment for the damage that occurs to the heart after myocardial infarction.[89][90]
In 2011 Neovasculgen was registered in Russia as the first-in-class gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for VEGF.[91][25] Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF.[92][93]
2012[edit]
The FDA approved Phase 1 clinical trials on thalassemia major patients in the US for 10 participants in July.[94] The study was expected to continue until 2015.[84]
In July 2012, the European Medicines Agency recommended approval of a gene therapy treatment for the first time in either Europe or the United States. The treatment used Alipogene tiparvovec (Glybera) to compensate for lipoprotein lipase deficiency, which can cause severe pancreatitis.[95] The recommendation was endorsed by the European Commission in November 2012[9][26][96][97] and commercial rollout began in late 2014.[98] Alipogene tiparvovec was expected to cost around $1.6 million per treatment in 2012,[99] revised to $1 million in 2015,[100] making it the most expensive medicine in the world at the time.[101] As of 2016, only one person had been treated with drug.[102]
In December 2012, it was reported that 10 of 13 patients with multiple myeloma were in remission "or very close to it" three months after being injected with a treatment involving genetically engineered T cells to target proteins NY-ESO-1 and LAGE-1, which exist only on cancerous myeloma cells.[21]
2013[edit]
In March researchers reported that three of five adult subjects who had acute lymphocytic leukemia (ALL) had been in remission for five months to two years after being treated with genetically modified T cells which attacked cells with CD19 genes on their surface, i.e. all B-cells, cancerous or not. The researchers believed that the patients' immune systems would make normal T-cells and B-cells after a couple of months. They were also given bone marrow. One patient relapsed and died and one died of a blood clot unrelated to the disease.[20]
Following encouraging Phase 1 trials, in April, researchers announced they were starting Phase 2 clinical trials (called CUPID2 and SERCA-LVAD) on 250 patients[103] at several hospitals to combat heart disease. The therapy was designed to increase the levels of SERCA2, a protein in heart muscles, improving muscle function.[104] The FDA granted this a Breakthrough Therapy Designation to accelerate the trial and approval process.[105] In 2016 it was reported that no improvement was found from the CUPID 2 trial.[106]
In July researchers reported promising results for six children with two severe hereditary diseases had been treated with a partially deactivated lentivirus to replace a faulty gene and after 7–32 months. Three of the children had metachromatic leukodystrophy, which causes children to lose cognitive and motor skills.[107] The other children had Wiskott-Aldrich syndrome, which leaves them to open to infection, autoimmune diseases, and cancer.[108] Follow up trials with gene therapy on another six children with Wiskott-Aldrich syndrome were also reported as promising.[109][110]
In October researchers reported that two children born with adenosine deaminase severe combined immunodeficiency disease (ADA-SCID) had been treated with genetically engineered stem cells 18 months previously and that their immune systems were showing signs of full recovery. Another three children were making progress.[17] In 2014 a further 18 children with ADA-SCID were cured by gene therapy.[111] ADA-SCID children have no functioning immune system and are sometimes known as "bubble children."[17]
Also in October researchers reported that they had treated six haemophilia sufferers in early 2011 using an adeno-associated virus. Over two years later all six were producing clotting factor.[17][112]
2014[edit]
In January researchers reported that six choroideremia patients had been treated with adeno-associated virus with a copy of REP1. Over a six-month to two-year period all had improved their sight.[113][114] By 2016, 32 patients had been treated with positive results and researchers were hopeful the treatment would be long-lasting.[14] Choroideremia is an inherited genetic eye disease with no approved treatment, leading to loss of sight.
In March researchers reported that 12 HIV patients had been treated since 2009 in a trial with a genetically engineered virus with a rare mutation (CCR5 deficiency) known to protect against HIV with promising results.[115][116]
Clinical trials of gene therapy for sickle cell disease were started in 2014.[117][118] There is a need for high quality randomised controlled trials assessing the risks and benefits involved with gene therapy for people with sickle cell disease.[119]
2015[edit]
In February LentiGlobin BB305, a gene therapy treatment undergoing clinical trials for treatment of beta thalassemia gained FDA "breakthrough" status after several patients were able to forgo the frequent blood transfusions usually required to treat the disease.[120]
In March researchers delivered a recombinant gene encoding a broadly neutralizing antibody into monkeys infected with simian HIV; the monkeys' cells produced the antibody, which cleared them of HIV. The technique is named immunoprophylaxis by gene transfer (IGT). Animal tests for antibodies to ebola, malaria, influenza, and hepatitis were underway.[121][122]
In March, scientists, including an inventor of CRISPR, Jennifer Doudna, urged a worldwide moratorium on germline gene therapy, writing "scientists should avoid even attempting, in lax jurisdictions, germline genome modification for clinical application in humans" until the full implications "are discussed among scientific and governmental organizations".[123][124][125][126]
In October, researchers announced that they had treated a baby girl, Layla Richards, with an experimental treatment using donor T-cells genetically engineered using TALEN to attack cancer cells. One year after the treatment she was still free of her cancer (a highly aggressive form of acute lymphoblastic leukaemia [ALL]).[127] Children with highly aggressive ALL normally have a very poor prognosis and Layla's disease had been regarded as terminal before the treatment.[128]
In December, scientists of major world academies called for a moratorium on inheritable human genome edits, including those related to CRISPR-Cas9 technologies[129] but that basic research including embryo gene editing should continue.[130]
2016[edit]
In April the Committee for Medicinal Products for Human Use of the European Medicines Agency endorsed a gene therapy treatment called Strimvelis[131][132] and the European Commission approved it in June.[133] This treats children born with adenosine deaminase deficiency and who have no functioning immune system. This was the second gene therapy treatment to be approved in Europe.[134]
In October, Chinese scientists reported they had started a trial to genetically modify T-cells from 10 adult patients with lung cancer and reinject the modified T-cells back into their bodies to attack the cancer cells. The T-cells had the PD-1 protein (which stops or slows the immune response) removed using CRISPR-Cas9.[135][136]
A 2016 Cochrane systematic review looking at data from four trials on topical cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy does not support its clinical use as a mist inhaled into the lungs to treat cystic fibrosis patients with lung infections. One of the four trials did find weak evidence that liposome-based CFTR gene transfer therapy may lead to a small respiratory improvement for people with CF. This weak evidence is not enough to make a clinical recommendation for routine CFTR gene therapy.[137]
2017[edit]
In February Kite Pharma announced results from a clinical trial of CAR-T cells in around a hundred people with advanced Non-Hodgkin lymphoma.[138]
In March, French scientists reported on clinical research of gene therapy to treat sickle-cell disease.[139]
In August, the FDA approved tisagenlecleucel for acute lymphoblastic leukemia.[140] Tisagenlecleucel is an adoptive cell transfer therapy for B-cell acute lymphoblastic leukemia; T cells from a person with cancer are removed, genetically engineered to make a specific T-cell receptor (a chimeric T cell receptor, or "CAR-T") that reacts to the cancer, and are administered back to the person. The T cells are engineered to target a protein called CD19 that is common on B cells. This is the first form of gene therapy to be approved in the United States. In October, a similar therapy called axicabtagene ciloleucel was approved for non-Hodgkin lymphoma.[141]
In December the results of using an adeno-associated virus with blood clotting factor VIII to treat nine haemophilia A patients were published. Six of the seven patients on the high dose regime increased the level of the blood clotting VIII to normal levels. The low and medium dose regimes had no effect on the patient's blood clotting levels.[142][143]
In December, the FDA approved Luxturna, the first in vivo gene therapy, for the treatment of blindness due to Leber's congenital amaurosis.[144] The price of this treatment was 850,000 US dollars for both eyes.[145][146] CRISPR gene editing technology has also been used on mice to treat deafness due to the DFNA36 mutation, which also affects humans.[147]
Speculative uses[edit]
Speculated uses for gene therapy include:
Fertility[edit]
Gene Therapy techniques have the potential to provide alternative treatments for those with infertility. Recently, successful experimentation on mice has proven that fertility can be restored by using the gene therapy method, CRISPR.[148] Spermatogenical stem cells from another organism were transplanted into the testes of an infertile male mouse. The stem cells re-established spermatogenesis and fertility.[149]
Gene doping[edit]
Main article: Gene doping
Athletes might adopt gene therapy technologies to improve their performance.[150] Gene doping is not known to occur, but multiple gene therapies may have such effects. Kayser et al. argue that gene doping could level the playing field if all athletes receive equal access. Critics claim that any therapeutic intervention for non-therapeutic/enhancement purposes compromises the ethical foundations of medicine and sports.[151]
Human genetic engineering[edit]
See also: Germinal choice technology and Human germline engineering
Genetic engineering could be used to cure diseases, but also to change physical appearance, metabolism, and even improve physical capabilities and mental faculties such as memory and intelligence. Ethical claims about germline engineering include beliefs that every fetus has a right to remain genetically unmodified, that parents hold the right to genetically modify their offspring, and that every child has the right to be born free of preventable diseases.[152][153][154] For parents, genetic engineering could be seen as another child enhancement technique to add to diet, exercise, education, training, cosmetics, and plastic surgery.[155][156] Another theorist claims that moral concerns limit but do not prohibit germline engineering.[157]
Possible regulatory schemes include a complete ban, provision to everyone, or professional self-regulation. The American Medical Association’s Council on Ethical and Judicial Affairs stated that "genetic interventions to enhance traits should be considered permissible only in severely restricted situations: (1) clear and meaningful benefits to the fetus or child; (2) no trade-off with other characteristics or traits; and (3) equal access to the genetic technology, irrespective of income or other socioeconomic characteristics."[158]
As early in the history of biotechnology as 1990, there have been scientists opposed to attempts to modify the human germline using these new tools,[159] and such concerns have continued as technology progressed.[160][161] With the advent of new techniques like CRISPR, in March 2015 a group of scientists urged a worldwide moratorium on clinical use of gene editing technologies to edit the human genome in a way that can be inherited.[123][124][125][126] In April 2015, researchers sparked controversy when they reported results of basic research to edit the DNA of non-viable human embryos using CRISPR.[148][162] A committee of the American National Academy of Sciences and National Academy of Medicine gave qualified support to human genome editing in 2017[163][164] once answers have been found to safety and efficiency problems "but only for serious conditions under stringent oversight."[165]
Regulations[edit]
Regulations covering genetic modification are part of general guidelines about human-involved biomedical research. There are no international treaties which are legally binding in this area, but there are recommendations for national laws from various bodies.
The Helsinki Declaration (Ethical Principles for Medical Research Involving Human Subjects) was amended by the World Medical Association's General Assembly in 2008. This document provides principles physicians and researchers must consider when involving humans as research subjects. The Statement on Gene Therapy Research initiated by the Human Genome Organization (HUGO) in 2001 provides a legal baseline for all countries. HUGO’s document emphasizes human freedom and adherence to human rights, and offers recommendations for somatic gene therapy, including the importance of recognizing public concerns about such research.[166]
United States[edit]
No federal legislation lays out protocols or restrictions about human genetic engineering. This subject is governed by overlapping regulations from local and federal agencies, including the Department of Health and Human Services, the FDA and NIH's Recombinant DNA Advisory Committee. Researchers seeking federal funds for an investigational new drug application, (commonly the case for somatic human genetic engineering,) must obey international and federal guidelines for the protection of human subjects.[167]
NIH serves as the main gene therapy regulator for federally funded research. Privately funded research is advised to follow these regulations. NIH provides funding for research that develops or enhances genetic engineering techniques and to evaluate the ethics and quality in current research. The NIH maintains a mandatory registry of human genetic engineering research protocols that includes all federally funded projects.
An NIH advisory committee published a set of guidelines on gene manipulation.[168] The guidelines discuss lab safety as well as human test subjects and various experimental types that involve genetic changes. Several sections specifically pertain to human genetic engineering, including Section III-C-1. This section describes required review processes and other aspects when seeking approval to begin clinical research involving genetic transfer into a human patient.[169] The protocol for a gene therapy clinical trial must be approved by the NIH's Recombinant DNA Advisory Committee prior to any clinical trial beginning; this is different from any other kind of clinical trial.[168]
As with other kinds of drugs, the FDA regulates the quality and safety of gene therapy products and supervises how these products are used clinically. Therapeutic alteration of the human genome falls under the same regulatory requirements as any other medical treatment. Research involving human subjects, such as clinical trials, must be reviewed and approved by the FDA and an Institutional Review Board.[170][171]
Popular culture[edit]
Gene therapy is the basis for the plotline of the film I Am Legend[172] and the TV show Will Gene Therapy Change the Human Race?.[173] It is also used in Stargate as a means of allowing humans to use Ancient technology.[174]
See also[edit]
Antisense therapy
Bioethics
Gene therapy for color blindness
Gene therapy for epilepsy
Gene therapy for osteoarthritis
Gene therapy in Parkinson's disease
Genetic engineering
Synthetic lethality
Synthetic rescue
Therapeutic gene modulation
References[edit]
Jump up ^ Ermak G (2015). Emerging Medical Technologies. World Scientific. ISBN 978-981-4675-81-9.
Jump up ^ Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, et al. (August 1990). "Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction". The New England Journal of Medicine. 323 (9): 570–8. doi:10.1056/NEJM199008303230904. PMID 2381442.
^ Jump up to: a b Gene Therapy Clinical Trials Worldwide Database. The Journal of Gene Medicine. Wiley (June 2016)
Jump up ^ Zimmer C (16 September 2013). "DNA Double Take". The New York Times.
Jump up ^ U.S. Congress, Office of Technology Assessment (December 1984). Human gene therapy – A background paper. DIANE Publishing. ISBN 978-1-4289-2371-3.
Jump up ^ Sun M (October 1982). "Martin Cline loses appeal on NIH grant". Science. 218 (4567): 37. doi:10.1126/science.7123214. PMID 7123214.
Jump up ^ Lowenstein P (2008). "Gene Therapy for Neurological Disorders: New Therapies or Human Experimentation?". In Burley J, Harris J. A Companion to Genethics. John Wiley & Sons. ISBN 978-0-470-75637-9.
^ Jump up to: a b Sheridan C (February 2011). "Gene therapy finds its niche". Nature Biotechnology. 29 (2): 121–8. doi:10.1038/nbt.1769. PMID 21301435.
^ Jump up to: a b c Richards S (6 November 2012). "Gene Therapy Arrives in Europe". The Scientist.
^ Jump up to: a b c Maguire AM, Simonelli F, Pierce EA, Pugh EN, Mingozzi F, Bennicelli J, et al. (May 2008). "Safety and efficacy of gene transfer for Leber's congenital amaurosis". The New England Journal of Medicine. 358 (21): 2240–8. doi:10.1056/NEJMoa0802315. PMC 2829748  . PMID 18441370.
^ Jump up to: a b Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL, et al. (March 2010). "Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration". Molecular Therapy. 18 (3): 643–50. doi:10.1038/mt.2009.277. PMC 2839440  . PMID 19953081.
^ Jump up to: a b Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL, Windsor EA, Conlon TJ, Sumaroka A, Roman AJ, Byrne BJ, Jacobson SG (August 2009). "Vision 1 year after gene therapy for Leber's congenital amaurosis". The New England Journal of Medicine. 361 (7): 725–7. doi:10.1056/NEJMc0903652. PMC 2847775  . PMID 19675341.
^ Jump up to: a b Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, et al. (May 2008). "Effect of gene therapy on visual function in Leber's congenital amaurosis". The New England Journal of Medicine. 358 (21): 2231–9. doi:10.1056/NEJMoa0802268. PMID 18441371.
^ Jump up to: a b Ghosh P (28 April 2016). "Gene therapy reverses sight loss and is long-lasting". BBC News, Science & Environment. Retrieved 29 April 2016.
Jump up ^ Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M (June 2010). "20 years of gene therapy for SCID". Nature Immunology. 11 (6): 457–60. doi:10.1038/ni0610-457. PMID 20485269.
Jump up ^ Ferrua F, Brigida I, Aiuti A (December 2010). "Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency". Current Opinion in Allergy and Clinical Immunology. 10 (6): 551–6. doi:10.1097/ACI.0b013e32833fea85. PMID 20966749.
^ Jump up to: a b c d e Geddes, Linda (30 October 2013) 'Bubble kid' success puts gene therapy back on track. The New Scientist. Retrieved 2 November 2013
Jump up ^ Cartier N, Aubourg P (July 2010). "Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy". Brain Pathology. 20 (4): 857–62. doi:10.1111/j.1750-3639.2010.00394.x. PMID 20626747.
^ Jump up to: a b Ledford H (2011). "Cell therapy fights leukaemia". Nature. doi:10.1038/news.2011.472.
^ Jump up to: a b Coghlan A (26 March 2013). "Gene therapy cures leukaemia in eight days". The New Scientist. Retrieved 15 April 2013.
^ Jump up to: a b Coghlan A (11 December 2013). "Souped-up immune cells force leukaemia into remission". New Scientist. Retrieved 15 April 2013.
Jump up ^ LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al. (April 2011). "AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial". The Lancet. Neurology. 10 (4): 309–19. doi:10.1016/S1474-4422(11)70039-4. PMID 21419704.
Jump up ^ Herper M (26 March 2014). "Gene Therapy's Big Comeback". Forbes. Retrieved 28 April 2014.
^ Jump up to: a b Pearson S, Jia H, Kandachi K (January 2004). "China approves first gene therapy". Nature Biotechnology. 22 (1): 3–4. doi:10.1038/nbt0104-3. PMID 14704685.
^ Jump up to: a b "Gene Therapy for PAD Approved". 6 December 2011. Retrieved 5 August 2015.
^ Jump up to: a b c Gallagher, James. (2 November 2012) BBC News – Gene therapy: Glybera approved by European Commission. BBC. Retrieved 15 December 2012.
Jump up ^ U.S. National Library of Medicine, Genomics Home Reference. What is gene therapy?
Jump up ^ U.S. National Library of Medicine, Genomics Home Reference. How does gene therapy work?
Jump up ^ Pezzoli D, Chiesa R, De Nardo L, Candiani G (September 2012). "We still have a long way to go to effectively deliver genes!". Journal of Applied Biomaterials & Functional Materials. 10 (2): 82–91. doi:10.5301/JABFM.2012.9707. PMID 23015375.
Jump up ^ Vannucci L, Lai M, Chiuppesi F, Ceccherini-Nelli L, Pistello M (January 2013). "Viral vectors: a look back and ahead on gene transfer technology". The New Microbiologica. 36 (1): 1–22. PMID 23435812.
Jump up ^ Gothelf A, Gehl J (November 2012). "What you always needed to know about electroporation based DNA vaccines". Human Vaccines & Immunotherapeutics. 8 (11): 1694–702. doi:10.4161/hv.22062. PMC 3601144  . PMID 23111168.
Jump up ^ Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD (September 2010). "Genome editing with engineered zinc finger nucleases". Nature Reviews. Genetics. 11 (9): 636–46. doi:10.1038/nrg2842. PMID 20717154.
Jump up ^ Porteus M (2016). "Genome Editing: A New Approach to Human Therapeutics". Annual Review of Pharmacology and Toxicology. 56: 163–90. doi:10.1146/annurev-pharmtox-010814-124454. PMID 26566154.
Jump up ^ Stone D, Niyonzima N, Jerome KR (September 2016). "Genome editing and the next generation of antiviral therapy". Human Genetics. 135 (9): 1071–82. doi:10.1007/s00439-016-1686-2. PMC 5002242  . PMID 27272125.
Jump up ^ Khan FA, Pandupuspitasari NS, Chun-Jie H, Ao Z, Jamal M, Zohaib A, Khan FA, Hakim MR, ShuJun Z (August 2016). "CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases". Oncotarget. 7 (32): 52541–52552. doi:10.18632/oncotarget.9646. PMID 27250031.
Jump up ^ Ledford H (12 October 2016). "CRISPR deployed to combat sickle-cell anaemia". Nature. Retrieved 13 October 2016.
Jump up ^ Grens K (13 October 2016). "CRISPR Corrects Sickle Cell-Causing Gene In Human Cells". The Scientist. Retrieved 10 October 2016.
Jump up ^ Mavilio F, Ferrari G (July 2008). "Genetic modification of somatic stem cells. The progress, problems and prospects of a new therapeutic technology". EMBO Reports. 9 Suppl 1: S64–9. doi:10.1038/embor.2008.81. PMC 3327547  . PMID 18578029.
^ Jump up to: a b c "International Law". The Genetics and Public Policy Center, Johns Hopkins University Berman Institute of Bioethics. 2010. Archived from the original on 2 September 2014.
Jump up ^ Strachnan T, Read AP (2004). Human Molecular Genetics (3rd ed.). Garland Publishing. p. 616. ISBN 978-0-8153-4184-0.
Jump up ^ Hanna K (2006). "Germline Gene Transfer". National Human Genome Research Institute.
Jump up ^ "Human Cloning and Genetic Modification". Association of Reproductive Health Officials. 2013. Archived from the original on 18 June 2013.
Jump up ^ "Gene Therapy". ama-assn.org. 4 April 2014. Retrieved 22 March 2015.
Jump up ^ Korthof G. "The implications of Steele's soma-to-germline feedback for human gene therapy".
Jump up ^ Woods NB, Bottero V, Schmidt M, von Kalle C, Verma IM (April 2006). "Gene therapy: therapeutic gene causing lymphoma". Nature. 440 (7088): 1123. Bibcode:2006Natur.440.1123W. doi:10.1038/4401123a. PMID 16641981.
Jump up ^ Thrasher AJ, Gaspar HB, Baum C, Modlich U, Schambach A, Candotti F, et al. (September 2006). "Gene therapy: X-SCID transgene leukaemogenicity". Nature. 443 (7109): E5–6; discussion E6–7. Bibcode:2006Natur.443E...5T. doi:10.1038/nature05219. PMID 16988659.
Jump up ^ Rojahn SY (11 February 2014). "Genome Surgery". MIT Technology Review. Retrieved 17 February 2014.
Jump up ^ Gene therapy needs a hero to live up to the hype. New Scientist (31 October 2013) . Retrieved 2 November 2012
Jump up ^ Crasto AM (7 July 2013). "Glybera – The Most Expensive Drug in the world & First Approved Gene Therapy in the West". All About Drugs. Retrieved 2 November 2013.
Jump up ^ ORNL.gov. ORNL.gov. Retrieved 15 December 2012.
Jump up ^ Frank KM, Hogarth DK, Miller JL, Mandal S, Mease PJ, Samulski RJ, Weisgerber GA, Hart J (July 2009). "Investigation of the cause of death in a gene-therapy trial". The New England Journal of Medicine. 361 (2): 161–9. doi:10.1056/NEJMoa0801066. PMID 19587341.
Jump up ^ Friedmann T, Roblin R (March 1972). "Gene therapy for human genetic disease?". Science. 175 (4025): 949–55. Bibcode:1972Sci...175..949F. doi:10.1126/science.175.4025.949. PMID 5061866.
Jump up ^ Rogers S, New Scientist 1970, p. 194
Jump up ^ Cepko CL, Roberts BE, Mulligan RC (July 1984). "Construction and applications of a highly transmissible murine retrovirus shuttle vector". Cell. 37 (3): 1053–62. doi:10.1016/0092-8674(84)90440-9. PMID 6331674.
Jump up ^ "The first gene therapy". Life Sciences Foundation. 21 June 2011. Archived from the original on 28 November 2012. Retrieved 7 January 2014.
Jump up ^ Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. (October 1995). "T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years". Science. 270 (5235): 475–80. Bibcode:1995Sci...270..475B. doi:10.1126/science.270.5235.475. PMID 7570001.
Jump up ^ Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J (January 1993). "Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA". Science. 259 (5091): 94–7. Bibcode:1993Sci...259...94T. doi:10.1126/science.8418502. PMID 8418502.
^ Jump up to: a b Trojan J, Pan YX, Wei MX, Ly A, Shevelev A, Bierwagen M, et al. (2012). "Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours". Chemotherapy Research and Practice. 2012: 721873. doi:10.1155/2012/721873. PMC 3287029  . PMID 22400112.
Jump up ^ Abbott A (April 1992). "Gene therapy. Italians first to use stem cells". Nature. 356 (6369): 465. Bibcode:1992Natur.356..465A. doi:10.1038/356465a0. PMID 1560817.
Jump up ^ Cavazzana-Calvo M, Thrasher A, Mavilio F (February 2004). "The future of gene therapy". Nature. 427 (6977): 779–81. Bibcode:2004Natur.427..779C. doi:10.1038/427779a. PMID 14985734.
Jump up ^ S; Blakeslee, Ra (1993-05-18). "Treatment for 'Bubble Boy Disease'". The New York Times. ISSN 0362-4331. Retrieved 2018-02-09.
Jump up ^ Stein R (11 October 2010). "First patient treated in stem cell study". The Washington Post. Retrieved 10 November 2010.
Jump up ^ "Death Prompts FDA to Suspend Arthritis Gene Therapy Trial". Medpage Today. 27 July 2007. Retrieved 10 November 2010.
Jump up ^ Stolberg SG (22 January 2000). "Gene Therapy Ordered Halted At University". The New York Times. Retrieved 10 November 2010.
Jump up ^ Wilson JF (18 March 2002). "Murine Gene Therapy Corrects Symptoms of Sickle Cell Disease". The Scientist – Magazine of the Life Sciences. Retrieved 17 August 2010.
Jump up ^ St. Jude Children's Research Hospital (4 December 2008). "Gene Therapy Corrects Sickle Cell Disease In Laboratory Study". ScienceDaily. Retrieved 29 December 2012.
Jump up ^ Penman D (11 October 2002). "Subtle gene therapy tackles blood disorder". New Scientist. Retrieved 17 August 2010.
Jump up ^ "DNA nanoballs boost gene therapy". New Scientist. 12 May 2002. Retrieved 17 August 2010.
Jump up ^ Ananthaswamy A (20 March 2003). "Undercover genes slip into the brain". New Scientist. Retrieved 17 August 2010.
Jump up ^ Holmes B (13 March 2003). "Gene therapy may switch off Huntington's". New Scientist. Retrieved 17 August 2010.
Jump up ^ Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. (April 2006). "Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1". Nature Medicine. 12 (4): 401–9. doi:10.1038/nm1393. PMID 16582916.
Jump up ^ Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L (May 2006). "Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer". Nature Medicine. 12 (5): 585–91. doi:10.1038/nm1398. PMID 16633348.
Jump up ^ Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. (October 2006). "Cancer regression in patients after transfer of genetically engineered lymphocytes". Science. 314 (5796): 126–9. Bibcode:2006Sci...314..126M. doi:10.1126/science.1129003. PMC 2267026  . PMID 16946036.
Jump up ^ Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, et al. (November 2006). "Gene transfer in humans using a conditionally replicating lentiviral vector". Proceedings of the National Academy of Sciences of the United States of America. 103 (46): 17372–7. Bibcode:2006PNAS..10317372L. doi:10.1073/pnas.0608138103. PMC 1635018  . PMID 17090675.
Jump up ^ "Penn Medicine presents HIV gene therapy trial data at CROI 2009". EurekAlert!. 10 February 2009. Retrieved 19 November 2009.
Jump up ^ "Gene therapy first for poor sight". BBC News. 1 May 2007. Retrieved 3 May 2010.
Jump up ^ Dolgin E (2009). "Colour blindness corrected by gene therapy". Nature. doi:10.1038/news.2009.921.
Jump up ^ Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, et al. (November 2009). "Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy". Science. 326 (5954): 818–23. Bibcode:2009Sci...326..818C. doi:10.1126/science.1171242. PMID 19892975.
Jump up ^ Komáromy AM, Alexander JJ, Rowlan JS, Garcia MM, Chiodo VA, Kaya A, et al. (July 2010). "Gene therapy rescues cone function in congenital achromatopsia". Human Molecular Genetics. 19 (13): 2581–93. doi:10.1093/hmg/ddq136. PMC 2883338  . PMID 20378608.
Jump up ^ Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, et al. (September 2010). "Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia". Nature. 467 (7313): 318–22. Bibcode:2010Natur.467..318C. doi:10.1038/nature09328. PMC 3355472  . PMID 20844535.
Jump up ^ Galanello R, Origa R (May 2010). "Beta-thalassemia". Orphanet Journal of Rare Diseases. 5: 11. doi:10.1186/1750-1172-5-11. PMC 2893117  . PMID 20492708.
^ Jump up to: a b Beals, Jacquelyn K. (16 September 2010). Gene Therapy Frees Beta-Thalassemia Patient From Transfusions for 2+ Years. Medscape.com (16 September 2010). Retrieved 15 December 2012.
^ Jump up to: a b Leboulch P (20 March 2013). "Five year outcome of lentiviral gene therapy for human beta-thalassemia, lessons and prospects". Thalassemia Reports. 3 (1s): 108.
^ Jump up to: a b Clinical trial number NCT01639690 for "β-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human β-Globin Gene" at ClinicalTrials.gov
Jump up ^ Trojan A, Aristizabal B, Jay LM, Castillo T, Penagos P, Trojan J. Testing of IGF-I biomarker in an ethical context. Adv Modern Onco Res, 2(4); 2016, doi:10.18282/amor:v2:i4.58
Jump up ^ Castillo T, Trojan A, Noguera MC, Jay ML, Crane C, Alvarez A, Melo G, Penagos PJ, Shevelev A, Aristizabal BH, Briceño I, Ayala A, Duc HT, Trojan J. Epistemiologic experience in elaboration of molecular biology technology for immunogene therapy (in Spanish). Rev Cien, 2 (25); 2016, doi:10.14483/udistrital.jour.RC.2016.25.a6
Jump up ^ Rosenberg, Tina (29 May 2011) The Man Who Had HIV and Now Does Not, New York.
Jump up ^ "Gene Therapy Turns Several Leukemia Patients Cancer Free. Will It Work for Other Cancers, Too?". Singularity Hub. Retrieved 7 January 2014.
Jump up ^ Yang ZJ, Zhang YR, Chen B, Zhang SL, Jia EZ, Wang LS, et al. (July 2009). "Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease". Molecular Biology Reports. 36 (6): 1323–9. doi:10.1007/s11033-008-9315-3. PMID 18649012.
Jump up ^ Hahn W, Pyun WB, Kim DS, Yoo WS, Lee SD, Won JH, et al. (October 2011). "Enhanced cardioprotective effects by coexpression of two isoforms of hepatocyte growth factor from naked plasmid DNA in a rat ischemic heart disease model". The Journal of Gene Medicine. 13 (10): 549–55. doi:10.1002/jgm.1603. PMID 21898720.
Jump up ^ AdisInsight Vascular endothelial growth factor gene therapy - HSCI Page accessed 5 June 2016
Jump up ^ Eurolab. Neovasculogen listing in Eurolab Page accessed 4 August 2015
Jump up ^ Deev RV, Bozo IY, Mzhavanadze ND, Voronov DA, Gavrilenko AV, Chervyakov YV, et al. (September 2015). "pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia". Journal of Cardiovascular Pharmacology and Therapeutics. 20 (5): 473–82. doi:10.1177/1074248415574336. PMID 25770117.
Jump up ^ "On Cancer: Launch of Stem Cell Therapy Trial Offers Hope for Patients with Inherited Blood Disorder". Memorial Sloan-Kettering Cancer Center. 16 July 2012. Retrieved 15 December 2012.
Jump up ^ Pollack, Andrew (20 July 2012) European Agency Backs Approval of a Gene Therapy, The New York Times.
Jump up ^ First Gene Therapy Approved by European Commission Archived 5 November 2012 at the Wayback Machine.. UniQure (2 November 2012). Retrieved 15 December 2012.
Jump up ^ "Chiesi and uniQure delay Glybera launch to add data". Biotechnology. The Pharma Letter. 4 August 2014. Retrieved 28 August 2014.
Jump up ^ Burger L, Hirschler B (26 November 2014). "First gene therapy drug sets million-euro price record". Reuters. Retrieved 30 March 2015.
Jump up ^ Whalen J (November 2, 2012). "Gene-Therapy Approval Marks Major Milestone". Wall Street Journal.
Jump up ^ Morrison C (March 3, 2015). "$1-million price tag set for Glybera gene therapy". TradeSecrets.
Jump up ^ Gene therapy approved in Europe for first time
Jump up ^ Regalado A (May 4, 2016). "The World's Most Expensive Medicine Is a Bust". MIT Technology Review.
Jump up ^ Bosely, Sarah (30 April 2013). "Pioneering gene therapy trials offer hope for heart patients". The Guardian. Retrieved 28 April 2014.
Jump up ^ First gene therapy trial for heart failure begins in UK. The Physicians Clinic (8 September 2013) Archived 29 April 2014 at the Wayback Machine.
Jump up ^ Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR(R), Novel, First-in-Class Therapy in Development to Treat Heart Failure. New York Times (10 April 2014)
Jump up ^ Fernàndez-Ruiz I (March 2016). "Gene therapy: No improvement in outcomes with gene therapy for heart failure". Nature Reviews. Cardiology. 13 (3): 122–3. doi:10.1038/nrcardio.2016.14. PMID 26843287.
Jump up ^ Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. (August 2013). "Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy". Science. 341 (6148): 1233158. doi:10.1126/science.1233158. PMID 23845948.
Jump up ^ Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, et al. (August 2013). "Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome". Science. 341 (6148): 1233151. doi:10.1126/science.1233151. PMC 4375961  . PMID 23845947.
Jump up ^ Gallagher, James (21 April 2015) Gene therapy: 'Tame HIV' used to cure disease BBC News, Health, Retrieved 21 April 2015
Jump up ^ Malech HL, Ochs HD (April 2015). "An emerging era of clinical benefit from gene therapy". Jama. 313 (15): 1522–3. doi:10.1001/jama.2015.2055. PMID 25898049.
Jump up ^ Gene therapy cure for children with 'bubble baby' disease. Science Daily (18 November 2014)
Jump up ^ Gene therapy provides safe, long-term relief for patients with severe hemophilia B. Science Daily (20 November 2014)
Jump up ^ MacLaren RE, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, Seymour L, Clark KR, During MJ, Cremers FP, Black GC, Lotery AJ, Downes SM, Webster AR, Seabra MC (March 2014). "Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial". Lancet. 383 (9923): 1129–37. doi:10.1016/S0140-6736(13)62117-0. PMC 4171740  . PMID 24439297.
Jump up ^ Beali, Abigail (25 January 2014) Gene therapy restores sight in people with eye disease The New Scientist. Retrieved 25 January 2014
Jump up ^ Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al. (March 2014). "Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV". The New England Journal of Medicine. 370 (10): 901–10. doi:10.1056/NEJMoa1300662. PMC 4084652  . PMID 24597865.
Jump up ^ Dvorsky, George (6 March 2014) Scientists Create Genetically Modified Cells That Protect Against HIV io9, Biotechnology. Retrieved 6 March 2014
Jump up ^ Clinical trial number NCT02247843 for "Stem Cell Gene Therapy for Sickle Cell Disease" at ClinicalTrials.gov
Jump up ^ Clinical trial number NCT00012545 for "Collection and Storage of Umbilical Cord Stem Cells for Treatment of Sickle Cell Disease" at ClinicalTrials.gov
Jump up ^ Olowoyeye A, Okwundu CI (November 2016). "Gene therapy for sickle cell disease". The Cochrane Database of Systematic Reviews. 11: CD007652. doi:10.1002/14651858.CD007652.pub5. PMID 27841932.
Jump up ^ "Ten things you might have missed Monday from the world of business". Boston Globe. 3 February 2015. Retrieved 13 February 2015.
Jump up ^ Zimmer C (9 March 2015). "Protection Without a Vaccine". The New York Times. Retrieved 30 March 2015.
Jump up ^ Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, et al. (March 2015). "AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges". Nature. 519 (7541): 87–91. Bibcode:2015Natur.519...87G. doi:10.1038/nature14264. PMC 4352131  . PMID 25707797.
^ Jump up to: a b Wade N (19 March 2015). "Scientists Seek Ban on Method of Editing the Human Genome". New York Times. Retrieved 20 March 2015.
^ Jump up to: a b Pollack A (3 March 2015). "A Powerful New Way to Edit DNA". New York Times. Retrieved 20 March 2015.
^ Jump up to: a b Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church G, et al. (April 2015). "Biotechnology. A prudent path forward for genomic engineering and germline gene modification". Science. 348 (6230): 36–8. Bibcode:2015Sci...348...36B. doi:10.1126/science.aab1028. PMC 4394183  . PMID 25791083.
^ Jump up to: a b Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J (March 2015). "Don't edit the human germ line". Nature. 519 (7544): 410–1. Bibcode:2015Natur.519..410L. doi:10.1038/519410a. PMID 25810189.
Jump up ^ Henry R (2017-02-19). "Leukaemia cure hopes rise as girl is gene‑edited". The Times. Retrieved 2017-02-20. (Registration required (help)).
Jump up ^ Sample I (5 November 2015). "Baby girl is first in the world to be treated with 'designer immune cells'". The Guardian. Retrieved 6 November 2015.
Jump up ^ Wade N (3 December 2015). "Scientists Place Moratorium on Edits to Human Genome That Could Be Inherited". New York Times. Retrieved 3 December 2015.
Jump up ^ Walsh F (3 December 2015). "Gene editing: Is era of designer humans getting closer?". BBC News Health. Retrieved 31 December 2015.
Jump up ^ "Summary of opinion1 (initial authorisation) Strimvelis" (PDF). European Medicines Agency. 1 April 2016. pp. 1–2. Retrieved 13 April 2016.
Jump up ^ Hirscheler B (1 April 2016). "Europe gives green light to first gene therapy for children". Reuters. Retrieved 13 April 2016.
Jump up ^ Reeves R (2016-06-06). "Second gene therapy wins approval in Europe". Bionews. Retrieved 2017-02-20.
Jump up ^ Coghlan A (9 April 2016). "Gene Therapy Approved" (3068). The New Scientist. pp. 8–9.
Jump up ^ Cyranoski D (July 2016). "Chinese scientists to pioneer first human CRISPR trial". Nature. 535 (7613): 476–7. doi:10.1038/nature.2016.20302. PMID 27466105.
Jump up ^ Bennett J (15 November 2016). "Chinese Scientists Become First to Use CRISPR Gene-Editing on Humans". Popular Mechanics. Retrieved 16 November 2016.
Jump up ^ Lee TW, Southern KW, Perry LA, Penny-Dimri JC, Aslam AA (June 2016). "Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease". The Cochrane Database of Systematic Reviews (6): CD005599. doi:10.1002/14651858.CD005599.pub5. PMID 27314455.
Jump up ^ Whipple T (2017-03-01). "New gene therapy 'shrinks tumours like ice cubes'". The Times. Retrieved 2017-03-01. (Subscription required (help)).
Jump up ^ Coghlan A (March 2017). "Gene therapy 'cures' boy of blood disease that affects millions". New Scientist.
Jump up ^ "FDA approval brings first gene therapy to the United States". FDA News Release. U.S. Food and Drug Administration. 30 August 2017.
Jump up ^ Research, Center for Drug Evaluation and. "Approved Drugs - FDA approves axicabtagene ciloleucel for large B-cell lymphoma". www.fda.gov. Retrieved 2018-01-05.
Jump up ^ Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, et al. (December 2017). "AAV5-Factor VIII Gene Transfer in Severe Hemophilia A". The New England Journal of Medicine. 377 (26): 2519–2530. doi:10.1056/nejmoa1708483. PMID 29224506.
Jump up ^ van den Berg HM (December 2017). "A Cure for Hemophilia within Reach". The New England Journal of Medicine. 377 (26): 2592–2593. doi:10.1056/nejme1713888. PMID 29224412.
Jump up ^ Office of the Commissioner (2017-12-19). "FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss". FDA. Retrieved 2017-12-20.
Jump up ^ Herper, Matthew (2018-01-03). "Spark Therapeutics Sets Price Of Blindness-Treating Gene Therapy At $850,000". Forbes. Retrieved 2018-01-04.
Jump up ^ Sheridan K (2017-12-19). "The FDA approved a gene therapy to treat blindness in a groundbreaking moment for DNA-based medicine". Newsweek. Retrieved 2017-12-20.
Jump up ^ One-off CRISPR treatment slows genetic hearing loss in mice
^ Jump up to: a b Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, Lv J, Xie X, Chen Y, Li Y, Sun Y, Bai Y, Songyang Z, Ma W, Zhou C, Huang J (May 2015). "CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes". Protein & Cell. 6 (5): 363–372. doi:10.1007/s13238-015-0153-5. PMC 4417674  . PMID 25894090.
Jump up ^ Wu Y, Zhou H, Fan X, Zhang Y, Zhang M, Wang Y, et al. (January 2015). "Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells". Cell Research. 25 (1): 67–79. doi:10.1038/cr.2014.160. PMC 4650588  . PMID 25475058.
Jump up ^ "WADA Gene Doping". WADA. Archived from the original on 21 November 2009. Retrieved 27 September 2013.
Jump up ^ Kayser B, Mauron A, Miah A (March 2007). "Current anti-doping policy: a critical appraisal". BMC Medical Ethics. 8: 2. doi:10.1186/1472-6939-8-2. PMC 1851967  . PMID 17394662.
Jump up ^ Powell R, Buchanan A (February 2011). "Breaking evolution's chains: the prospect of deliberate genetic modification in humans". The Journal of Medicine and Philosophy. 36 (1): 6–27. doi:10.1093/jmp/jhq057. PMID 21228084.
Jump up ^ Baylis F, Robert JS (2004). "The inevitability of genetic enhancement technologies". Bioethics. 18 (1): 1–26. doi:10.1111/j.1467-8519.2004.00376.x. PMID 15168695.
Jump up ^ Evans J (2002). Playing God?: Human Genetic Engineering and the Rationalization of Public Bioethical Debate. University of Chicago Press. ISBN 978-0-226-22262-2.
Jump up ^ Gene Therapy and Genetic Engineering. Archived 3 December 2013 at the Wayback Machine. The Center for Health Ethics, University of Missouri School of Medicine. 25 April 2013.
Jump up ^ Roco MC, Bainbridge WS (2002). "Converging Technologies for Improving Human Performance: Integrating From the Nanoscale". Journal of Nanoparticle Research. 4 (4): 281–295. doi:10.1023/A:1021152023349.
Jump up ^ Allhoff F (March 2005). "Germ-line genetic enhancement and Rawlsian primary goods" (PDF). Kennedy Institute of Ethics Journal. 15 (1): 39–56. doi:10.1353/ken.2005.0007. PMID 15881795.
Jump up ^ "Ethical issues related to prenatal genetic testing. The Council on Ethical and Judicial Affairs, American Medical Association". Archives of Family Medicine. 3 (7): 633–42. July 1994. doi:10.1001/archfami.3.7.633. PMID 7921302.
Jump up ^ The Declaration of Inuyama: Human Genome Mapping, Genetic Screening and Gene Therapy. cioms.ch
Jump up ^ Smith KR, Chan S, Harris J (October 2012). "Human germline genetic modification: scientific and bioethical perspectives". Archives of Medical Research. 43 (7): 491–513. doi:10.1016/j.arcmed.2012.09.003. PMID 23072719.
Jump up ^ Reardon S (14 February 2017). "US science advisers outline path to genetically modified babies". Nature. doi:10.1038/nature.2017.21474  .
Jump up ^ Kolata G (23 April 2015). "Chinese Scientists Edit Genes of Human Embryos, Raising Concerns". New York Times. Retrieved 24 April 2015.
Jump up ^ Harmon A (2017-02-14). "Human Gene Editing Receives Science Panel's Support". The New York Times. ISSN 0362-4331. Retrieved 2017-02-17.
Jump up ^ Committee on Human Gene Editing: Scientific, Medical, and Ethical Considerations. "Human Genome Editing: Science, Ethics, and Governance". nationalacademies.org. National Academy of Sciences; National Academy of Medicine. Retrieved 21 February 2017. CS1 maint: Multiple names: authors list (link)
Jump up ^ "Scientists OK genetically engineering babies". New York Post. Reuters. 2017-02-14. Retrieved 2017-02-17.
Jump up ^ Human Genome Organization. HUGO Ethics Committee (April 2001). Statement on Gene Therapy Research.
Jump up ^ Isasi RM, Nguyen TM, Knoppers BM (October 2006). "National Regulatory Frameworks Regarding Human Genetic Modification Technologies (Somatic and Germline Modification)" (PDF). Genetics & Public Policy Center. Archived from the original (PDF) on 17 September 2014.
^ Jump up to: a b National Institutes of Health. NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. Revised April 2016.
Jump up ^ U.S. Department of Health & Human Services. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. 18 April 1979.
Jump up ^ U.S. Food and Drug Administration (14 October 1993). "Application of Current Statutory Authorities to Human Somatic Cell Therapy Products and Gene Therapy Products" (PDF). Federal Register. 58 (197).
Jump up ^ U.S. Department of Health and Human Services. Food and Drug Administration. Center for Biologics Evaluation and Research. Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy. March 1998.
Jump up ^ "A Real-life 'I Am Legend?' Researcher Champions Development Of 'Reovirus' As Potential Treatment For Cancer". Sciencedaily.com. 9 May 2008. Retrieved 17 August 2010.
Jump up ^ Race?/ Gene therapy on IMDb
Jump up ^ Cass S (15 September 2008). "Stargate Atlantis: Gene Therapy". Discover. Retrieved 14 December 2016.
Further reading[edit]
Tinkov S, Bekeredjian R, Winter G, Coester C (20 November 2000). "Polyplex-conjugated microbubbles for enhanced ultrasound targeted gene therapy" (PDF). Georgia World Congress Center, Atlanta, GA, USA: 2008 AAPS Annual Meeting and Exposition.
Gardlík R, Pálffy R, Hodosy J, Lukács J, Turna J, Celec P (April 2005). "Vectors and delivery systems in gene therapy". Medical Science Monitor. 11 (4): RA110–21. PMID 15795707.
Staff (18 November 2005). "Gene Therapy" (FAQ). Human Genome Project Information. Oak Ridge National Laboratory. Retrieved 28 May 2006.
Salmons B, Günzburg WH (April 1993). "Targeting of retroviral vectors for gene therapy". Human Gene Therapy. 4 (2): 129–41. doi:10.1089/hum.1993.4.2-129. PMID 8494923.
Baum C, Düllmann J, Li Z, Fehse B, Meyer J, Williams DA, von Kalle C (March 2003). "Side effects of retroviral gene transfer into hematopoietic stem cells". Blood. 101 (6): 2099–114. doi:10.1182/blood-2002-07-2314. PMID 12511419.
Horn PA, Morris JC, Neff T, Kiem HP (September 2004). "Stem cell gene transfer--efficacy and safety in large animal studies". Molecular Therapy. 10 (3): 417–31. doi:10.1016/j.ymthe.2004.05.017. PMID 15336643.
Wang H, Shayakhmetov DM, Leege T, Harkey M, Li Q, Papayannopoulou T, Stamatoyannopolous G, Lieber A (September 2005). "A capsid-modified helper-dependent adenovirus vector containing the beta-globin locus control region displays a nonrandom integration pattern and allows stable, erythroid-specific gene expression". Journal of Virology. 79 (17): 10999–1013. doi:10.1128/JVI.79.17.10999-11013.2005. PMC 1193620  . PMID 16103151.
External links[edit]
Wikibooks has a book on the topic of: Genes, Technology and Policy
[show]
v
t
e
Genetic engineering
Genetically
modified
organisms
Crops
Maize
MON 810
MON 863
StarLink
List of varieties of genetically modified maize
Potato
Amflora
Rice
Golden rice
Soybean
Roundup ready soybean
Vistive Gold
Tomato
Flavr Savr
Cotton
Bt cotton
Other
Apple
Arabidopsis
Brinjal
Canola
Papaya
Rose
SmartStax
Sugar beet
Tobacco
Trees
Wheat
Mammals
Mouse
Knockout mouse
Oncomouse
Enviropig
Herman the Bull
Knockout rat
Other animals
Insects
Fish
Glofish
Salmon
Birds
Frogs
Bacteria
and viruses
Ice-minus bacteria
Hepatitis B vaccine
Oncolytic virus
Processes
Inserting DNA
Agrobacteria
Biolistics
Electroporation
Genetic transduction
Lipofection
Microinjection
Somatic cell nuclear transfer
Transfection
Types
Recombinant DNA
Transgenesis
Cisgenesis
Uses
In agriculture
Genetically modified food
Controversies
Pharming
Companies
BASF
Bayer
Dow AgroSciences
DuPont Pioneer
Monsanto
Syngenta
In humans and
diagnostics
Gene therapy
Genetic enhancement
In research
Gene knockout
Gene knockdown
Gene targeting
Related
articles
Transgene
Detection of genetically modified organisms
Genetic pollution
Genetic engineering in fiction
Human enhancement
Reverse transfection
Transhumanism
Regulation
Cartagena Protocol on Biosafety
Geography
Europe
Africa
Asia
North America (US)
South America
Oceania
Similar fields
Synthetic biology
Cloning
Stem cell research
Biology
Genetics
Biotechnology
Bioethics
[show]
v
t
e
Emerging technologies
Fields
Agriculture
Agricultural robot
Closed ecological systems
Cultured meat
Genetically modified food
Precision agriculture
Vertical farming
Architecture
Arcology
Building printing
Contour crafting
Domed city
Biomedical
Artificial uterus
Ampakine
Brain transplant
Cryonics
Cryoprotectant
Cryopreservation
Vitrification
Suspended animation
De-extinction
Genetic engineering
Gene therapy
Head transplant
Isolated brain
Life extension
Strategies for Engineered Negligible Senescence
Nanomedicine
Nanosensors
Personalized medicine
Regenerative medicine
Stem-cell therapy
Tissue engineering
Robot-assisted surgery
Synthetic biology
Synthetic genomics
Virotherapy
Oncolytic virus
Tricorder
Whole genome sequencing
Displays
Next generation
FED
FLCD
iMoD
Laser
LPD
OLED
OLET
QD-LED
SED
TPD
TDEL
TMOS
Screenless
Bionic contact lens
Head-mounted display
Head-up display
Optical head-mounted display
Virtual retinal display
Other
Autostereoscopy
Flexible display
Holographic display
Computer-generated holography
Multi-primary color display
Ultra HD
Volumetric display
Electronics
Electronic nose
E-textiles
Flexible electronics
Molecular electronics
Nanoelectromechanical systems
Memristor
Spintronics
Thermal copper pillar bump
Energy
Production
Airborne wind turbine
Artificial photosynthesis
Biofuels
Carbon-neutral fuel
Concentrated solar power
Fusion power
Home fuel cell
Hydrogen economy
Methanol economy
Molten salt reactor
Nantenna
Photovoltaic pavement
Space-based solar power
Vortex engine
Storage
Beltway battery
Compressed air energy storage
Flywheel energy storage
Grid energy storage
Lithium–air battery
Molten-salt battery
Nanowire battery
Research in lithium-ion batteries
Silicon–air battery
Thermal energy storage
Ultracapacitor
Other
Smart grid
Wireless power
Information and
communications
Ambient intelligence
Internet of things
Artificial intelligence
Applications of artificial intelligence
Progress in artificial intelligence
Machine translation
Mobile translation
Machine vision
Semantic Web
Speech recognition
Atomtronics
Carbon nanotube field-effect transistor
Cybermethodology
Fourth-generation optical discs
3D optical data storage
Holographic data storage
GPGPU
Memory
CBRAM
FRAM
Millipede
MRAM
NRAM
PRAM
Racetrack memory
RRAM
SONOS
Optical computing
RFID
Chipless RFID
Software-defined radio
Three-dimensional integrated circuit
Manufacturing
3D printing
Claytronics
Molecular assembler
Utility fog
Materials science
Aerogel
Amorphous metal
Artificial muscle
Conductive polymer
Femtotechnology
Fullerene
Graphene
High-temperature superconductivity
High-temperature superfluidity
Linear acetylenic carbon
Metamaterials
Metamaterial cloaking
Metal foam
Multi-function structures
Nanotechnology
Carbon nanotubes
Molecular nanotechnology
Nanomaterials
Picotechnology
Programmable matter
Quantum dots
Silicene
Superalloy
Synthetic diamond
Military
Antimatter weapon
Caseless ammunition
Directed-energy weapon
Laser
Maser
Particle-beam weapon
Sonic weapon
Coilgun
Railgun
Plasma weapon
Pure fusion weapon
Stealth technology
Vortex ring gun
Neuroscience
Artificial brain
Brain–computer interface
Electroencephalography
Mind uploading
Brain-reading
Neuroinformatics
Neuroprosthetics
Bionic eye
Brain implant
Exocortex
Retinal implant
Quantum
Quantum algorithms
Quantum amplifier
Quantum bus
Quantum channel
Quantum circuit
Quantum complexity theory
Quantum computing
Quantum cryptography
Quantum dynamics
Quantum electronics
Quantum error correction
Quantum imaging
Quantum information
Quantum key distribution
Quantum logic
Quantum logic gates
Quantum machine
Quantum machine learning
Quantum metamaterial
Quantum metrology
Quantum network
Quantum neural network
Quantum optics
Quantum programming
Quantum sensing
Quantum simulator
Quantum teleportation
Robotics
Domotics
Nanorobotics
Powered exoskeleton
Self-reconfiguring modular robot
Swarm robotics
Uncrewed vehicle
Space science
Launch
Fusion rocket
Non-rocket spacelaunch
Mass driver
Orbital ring
Skyhook
Space elevator
Space fountain
Space tether
Reusable launch system
Propulsion
Beam-powered propulsion
Ion thruster
Laser propulsion
Plasma propulsion engine
Helicon thruster
VASIMR
Nuclear pulse propulsion
Solar sail
Other
Interstellar travel
Propellant depot
Transport
Aerial
Adaptive compliant wing
Backpack helicopter
Delivery drone
Flying car
High-altitude platform
Jet pack
Pulse detonation engine
Scramjet
Spaceplane
Supersonic transport
Land
Airless tire
Alternative fuel vehicle
Hydrogen vehicle
Driverless car
Ground effect train
Maglev train
Personal rapid transit
Vactrain
Vehicular communication systems
Pipeline
Pneumatic transport
Automated vacuum collection
Other
Anti-gravity
Cloak of invisibility
Digital scent technology
Force field
Plasma window
Immersive virtual reality
Magnetic refrigeration
Phased-array optics
Topics
Collingridge dilemma
Differential technological development
Disruptive Innovation
Ephemeralization
Exploratory engineering
Fictional technology
Proactionary principle
Technological change
Technological unemployment
Technological convergence
Technological evolution
Technological paradigm
Technology forecasting
Accelerating change
Moore's law
Technological singularity
Technology scouting
Technology readiness level
Technology roadmap
Transhumanism
Category
List
Authority control
GND: 4296957-8
NDL: 00925603
Retrieved from "https://en.wikipedia.org/w/index.php?title=Gene_therapy&oldid=828153560"
Categories:
Applied genetics
Bioethics
Biotechnology
Medical genetics
Medical research
Molecular biology
Gene delivery
Emerging technologies
1989 introductions
1996 introductions
Gene therapy
1989 in biotechnology
Genetic engineering
Hidden categories:
Webarchive template wayback links
Pages with login required references or sources
Pages containing links to subscription-only content
CS1 maint: Multiple names: authors list
Use dmy dates from December 2016
All articles with unsourced statements
Articles with unsourced statements from January 2018
Articles with unsourced statements from June 2015
Wikipedia articles with GND identifiers
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Article
Talk
Variants
Views
Read
Edit
View history
More
Search
Navigation
Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikipedia store
Interaction
Help
About Wikipedia
Community portal
Recent changes
Contact page
Tools
What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Wikidata item
Cite this page
Print/export
Create a book
Download as PDF
Printable version
In other projects
Wikimedia Commons
Languages
العربية
Bosanski
Català
Čeština
Dansk
Deutsch
Eesti
Español
Esperanto
Euskara
فارسی
Français
Galego
한국어
हिन्दी
Bahasa Indonesia
Italiano
עברית
Basa Jawa
ಕನ್ನಡ
Kreyòl ayisyen
Magyar
മലയാളം
Nederlands
日本語
Norsk
Polski
Português
Русский
Simple English
Slovenščina
کوردی
Srpskohrvatski / српскохрватски
Suomi
Svenska
தமிழ்
తెలుగు
ไทย
Türkçe
Українська
اردو
中文
33 more
Edit links
This page was last edited on 28 February 2018, at 21:42.
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.
Privacy policy
About Wikipedia
Disclaimers
Contact Wikipedia
Developers
Cookie statement
Mobile view
Enable previews

key: html

type: local

value: div

attrs: id class

values: mw-page-base noprint

values: mw-head-base noprint

value: a

attrs: id class lang

values: firstHeading firstHeading en

values: siteSub noprint

values: jump-to-nav mw-jump

value: img

attrs: href class

values: /wiki/Adenovirus mw-redirect Adenovirus

attrs: href title

attrs: class style

value: b

values:
/wiki/Biopharmaceutical_drug
mw-redirect
Biopharmaceutical drug

value: sup

values:
/wiki/French_Anderson
mw-redirect
French Anderson

values:
/wiki/Bone_marrow_transplantation
mw-redirect
Bone marrow transplantation

values:
/wiki/Organ_transplants
mw-redirect
Organ transplants

values: This claim needs references to reliable sources. (January 2018)

values:
noprint Inline-Template Template-Fact
white-space:nowrap;

values:
/wiki/Genetic_mutations
mw-redirect
Genetic mutations

values:
/wiki/Retinal_diseases
mw-redirect
Retinal diseases

values: X-linked severe combined immunodeficiency

values:
/wiki/Acute_lymphocytic_leukemia
mw-redirect
Acute lymphocytic leukemia

values:
/wiki/Inherited_disorder
mw-redirect
Inherited disorder

values:
/wiki/Sickle_cell_anemia
mw-redirect
Sickle cell anemia

values:
/wiki/Zinc_finger_nucleases
mw-redirect
Zinc finger nucleases

values:
/wiki/Clinical_trials
mw-redirect
Clinical trials

values:
/wiki/Vectors_in_Gene_Therapy
mw-redirect
Vectors in Gene Therapy

values:
/wiki/Vaccinia_virus
mw-redirect
Vaccinia virus

values: This claim needs references to reliable sources. (June 2015)

values:
/wiki/Heart_disease
mw-redirect
Heart disease

values:
/wiki/High_blood_pressure
mw-redirect
High blood pressure

values:
/wiki/T_cell_leukemia
mw-redirect
T cell leukemia

values:
/wiki/Hereditary_diseases
mw-redirect
Hereditary diseases

values:
/wiki/Severe_combined_immune_deficiency
mw-redirect
Severe combined immune deficiency

values:
/wiki/Genetic_screening
mw-redirect
Genetic screening

values:
/wiki/Double-stranded_RNA
mw-redirect
Double-stranded RNA

values:
/wiki/Tumor_suppressor
mw-redirect
Tumor suppressor

values:
/wiki/Organ_transplant
mw-redirect
Organ transplant

values:
/wiki/HIV_envelope
mw-redirect
HIV envelope

values:
/wiki/Phase_I_clinical_trial
mw-redirect
Phase I clinical trial

values:
/wiki/Retinal_disease
mw-redirect
Retinal disease

values:
/wiki/Trichromatic_vision
mw-redirect
Trichromatic vision

values:
/wiki/Squirrel_monkeys
mw-redirect
Squirrel monkeys

values:
/wiki/Cone_(vision)
mw-redirect
Cone (vision)

values:
/wiki/Blood_disease
mw-redirect
Blood disease

values:
/wiki/Blood_transfusions
mw-redirect
Blood transfusions

values:
/wiki/Bone_marrow_transplant
mw-redirect
Bone marrow transplant

values:
/wiki/Ablation_therapy
mw-redirect
Ablation therapy

values:
/wiki/Wiskott-Aldrich_syndrome
mw-redirect
Wiskott-Aldrich syndrome

values:
/wiki/Clotting_factor
mw-redirect
Clotting factor

values:
/wiki/Rab_escort_protein
mw-redirect
Rab escort protein

values:
/wiki/Sickle_cell_disease
mw-redirect
Sickle cell disease

values:
/wiki/Recombinant_gene
mw-redirect
Recombinant gene

values:
/wiki/Broadly_neutralizing_antibody
mw-redirect
Broadly neutralizing antibody

values: Transcription activator-like effector nuclease

values:
/wiki/Acute_lymphoblastic_leukaemia
mw-redirect
Acute lymphoblastic leukaemia

values: Committee for Medicinal Products for Human Use

values: Cystic fibrosis transmembrane conductance regulator

values:
/wiki/Genetically_engineered
mw-redirect
Genetically engineered

values:
/wiki/Human_embryos
mw-redirect
Human embryos

values:
/wiki/Human_Genome_Organization
mw-redirect
Human Genome Organization

values:
/wiki/Institutional_Review_Board
mw-redirect
Institutional Review Board

values:
nofollow
external text
//doi.org/10.1056%2FNEJM199008303230904

values:
/wiki/PubMed_Identifier
mw-redirect
PubMed Identifier

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/2381442

values:
nofollow
external text
http://www.abedia.com/wiley/phases.php

values:
nofollow
external text
//doi.org/10.1126%2Fscience.7123214

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/7123214

values:
nofollow
external text
//doi.org/10.1038%2Fnbt.1769

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21301435

values:
nofollow
external text
//doi.org/10.1056%2FNEJMoa0802315

attrs: alt src title width height srcset data-file-width data-file-height

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18441370

values:
nofollow
external text
//doi.org/10.1038%2Fmt.2009.277

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19953081

values:
nofollow
external text
//doi.org/10.1056%2FNEJMc0903652

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19675341

values:
nofollow
external text
//doi.org/10.1056%2FNEJMoa0802268

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18441371

values:
nofollow
external text
//doi.org/10.1038%2Fni0610-457

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20485269

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20966749

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20626747

values:
nofollow
external text
//doi.org/10.1038%2Fnews.2011.472

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21419704

values:
nofollow
external text
//doi.org/10.1038%2Fnbt0104-3

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/14704685

values:
nofollow
external text
//doi.org/10.5301%2FJABFM.2012.9707

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23015375

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23435812

values:
nofollow
external text
//doi.org/10.4161%2Fhv.22062

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23111168

values:
nofollow
external text
//doi.org/10.1038%2Fnrg2842

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20717154

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26566154

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27272125

values:
nofollow
external text
//doi.org/10.18632%2Foncotarget.9646

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27250031

values:
nofollow
external text
//doi.org/10.1038%2Fembor.2008.81

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18578029

values:
nofollow
external text
http://www.genome.gov/10004764

values:
nofollow
external text
http://wasdarwinwrong.com/kortho39a.htm

values:
nofollow
external text
//doi.org/10.1038%2F4401123a

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16641981

values:
nofollow
external text
//doi.org/10.1038%2Fnature05219

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16988659

values:
nofollow
external text
//doi.org/10.1056%2FNEJMoa0801066

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19587341

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/5061866

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/6331674

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/7570001

values:
nofollow
external text
//doi.org/10.1126%2Fscience.8418502

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8418502

values:
nofollow
external text
//doi.org/10.1155%2F2012%2F721873

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22400112

values:
nofollow
external text
//doi.org/10.1038%2F356465a0

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1560817

values:
nofollow
external text
//doi.org/10.1038%2F427779a

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/14985734

values:
nofollow
external text
//www.worldcat.org/issn/0362-4331

values:
nofollow
external text
//doi.org/10.1038%2Fnm1393

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16582916

values:
nofollow
external text
//doi.org/10.1038%2Fnm1398

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16633348

values:
nofollow
external text
//doi.org/10.1126%2Fscience.1129003

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16946036

values:
nofollow
external text
//doi.org/10.1073%2Fpnas.0608138103

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17090675

values:
nofollow
external text
//doi.org/10.1038%2Fnews.2009.921

values:
nofollow
external text
//doi.org/10.1126%2Fscience.1171242

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19892975

values:
nofollow
external text
//doi.org/10.1093%2Fhmg%2Fddq136

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20378608

values:
nofollow
external text
//doi.org/10.1038%2Fnature09328

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20844535

values:
nofollow
external text
//doi.org/10.1186%2F1750-1172-5-11

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20492708

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18649012

values:
nofollow
external text
//doi.org/10.1002%2Fjgm.1603

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21898720

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25770117

values:
nofollow
external text
//doi.org/10.1038%2Fnrcardio.2016.14

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26843287

values:
nofollow
external text
//doi.org/10.1126%2Fscience.1233158

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23845948

values:
nofollow
external text
//doi.org/10.1126%2Fscience.1233151

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23845947

values:
nofollow
external text
//doi.org/10.1001%2Fjama.2015.2055

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25898049

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/24439297

values:
nofollow
external text
//doi.org/10.1056%2FNEJMoa1300662

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/24597865

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27841932

values:
/wiki/Boston_Globe
mw-redirect
Boston Globe

values:
nofollow
external text
//doi.org/10.1038%2Fnature14264

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25707797

values:
/wiki/New_York_Times
mw-redirect
New York Times

values:
nofollow
external text
//doi.org/10.1126%2Fscience.aab1028

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25791083

values:
nofollow
external text
//doi.org/10.1038%2F519410a

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25810189

values: The site requires registration to access this page.

values:
nofollow
external text
//doi.org/10.1038%2Fnature.2016.20302

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27466105

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27314455

values: The site requires a paid subscription to access this page.

values:
nofollow
external text
//doi.org/10.1056%2Fnejmoa1708483

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/29224506

values:
nofollow
external text
//doi.org/10.1056%2Fnejme1713888

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/29224412

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25894090

values:
nofollow
external text
//doi.org/10.1038%2Fcr.2014.160

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25475058

values:
nofollow
external text
//doi.org/10.1186%2F1472-6939-8-2

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17394662

values:
nofollow
external text
//doi.org/10.1093%2Fjmp%2Fjhq057

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21228084

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15168695

values:
nofollow
external text
//doi.org/10.1023%2FA%3A1021152023349

values:
nofollow
external text
http://jetpress.org/v18/allhoff.pdf

values:
nofollow
external text
//doi.org/10.1353%2Fken.2005.0007

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15881795

values:
nofollow
external text
//doi.org/10.1001%2Farchfami.3.7.633

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/7921302

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23072719

values:
nofollow
external text
//doi.org/10.1038%2Fnature.2017.21474

values: Category:CS1 maint: Multiple names: authors list

values:
nofollow
external text
http://www.imdb.com/title/ttn

values: -moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15795707

values:
nofollow
external text
//doi.org/10.1089%2Fhum.1993.4.2-129

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8494923

values:
nofollow
external text
//doi.org/10.1182%2Fblood-2002-07-2314

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12511419

values:
nofollow
external text
//doi.org/10.1016%2Fj.ymthe.2004.05.017

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15336643

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16103151

values: -moz-column-width: 35em; -webkit-column-width: 35em; column-width: 35em;

values: List of varieties of genetically modified maize

values:
/wiki/Genetically_modified_potato
mw-redirect
Genetically modified potato

values:
/wiki/Roundup_ready_soybean
mw-redirect
Roundup ready soybean

values:
/wiki/Genetically_modified_salmon
mw-redirect
Genetically modified salmon

values:
/wiki/Genetically_modified_bacteria
mw-redirect
Genetically modified bacteria

values:
/wiki/Genetic_transduction
mw-redirect
Genetic transduction

values:
/wiki/Human_genetic_engineering
mw-redirect
Human genetic engineering

values:
/wiki/Genetic_enhancement
mw-redirect
Genetic enhancement

values: Detection of genetically modified organisms

values:
/wiki/Genetic_engineering_in_fiction
mw-redirect
Genetic engineering in fiction

values: Genetic engineering in the United States

values: nowraplinks hlist collapsible autocollapse navbox-inner

values:
row
navbox-group
text-align: center;;width:1%

values:
row
navbox-group
width:1%;text-align: center;

values: Strategies for Engineered Negligible Senescence

values: Thick-film dielectric electroluminescent technology

values:
/wiki/Photovoltaic_pavement
mw-redirect
Photovoltaic pavement

values: Information and communications technology

values: General-purpose computing on graphics processing units

values:
/wiki/Quantum_electronics
mw-redirect
Quantum electronics

values: Variable Specific Impulse Magnetoplasma Rocket

values:
/wiki/Disruptive_Innovation
mw-redirect
Disruptive Innovation

values: nowraplinks hlist collapsible collapsed navbox-inner

values:
nofollow
external text
https://d-nb.info/gnd/4296957-8

values: Category:Webarchive template wayback links

values: Category:Pages with login required references or sources

values: Category:Pages containing links to subscription-only content

values: Category:Use dmy dates from December 2016

values: Category:All articles with unsourced statements

values: Category:Articles with unsourced statements from January 2018

values: Category:Articles with unsourced statements from June 2015

values: Category:Wikipedia articles with GND identifiers

values: Discussion about edits from this IP address [ctrl-alt-n]

values: A list of edits made from this IP address [ctrl-alt-y]

values: You are encouraged to create an account and log in; however, it is not mandatory

values: You're encouraged to log in; however, it's not mandatory. [ctrl-alt-o]

values:
/wiki/Gene_therapy
View the content page [ctrl-alt-c]
c

values: Discussion about the content page [ctrl-alt-t]

values: p-namespaces navigation vectorTabs p-namespaces-label

values:
p-variants
navigation
vectorMenu emptyPortlet
p-variants-label

values: Past revisions of this page [ctrl-alt-h]

values: p-views navigation vectorTabs p-views-label

values:
p-cactions
navigation
vectorMenu emptyPortlet
p-cactions-label

values:
mw-wiki-logo
/wiki/Main_Page
Visit the main page

values:
/wiki/Main_Page
Visit the main page [ctrl-alt-z]
z

values: Featured content – the best of Wikipedia

values: Find background information on current events

values:
/wiki/Special:Random
Load a random article [ctrl-alt-x]
x

values: portal navigation p-navigation p-navigation-label

values: Guidance on how to use and edit Wikipedia

values: About the project, what you can do, where to find things

values: A list of recent changes in the wiki [ctrl-alt-r]

values: portal navigation p-interaction p-interaction-label

values: List of all English Wikipedia pages containing links to this page [ctrl-alt-j]

values: Recent changes in pages linked from this page [ctrl-alt-k]

values:
/wiki/Wikipedia:File_Upload_Wizard
Upload files [ctrl-alt-u]
u

values: A list of all special pages [ctrl-alt-q]

values: Permanent link to this revision of the page

values: Link to connected data repository item [ctrl-alt-g]

values: Printable version of this page [ctrl-alt-p]

values: portal navigation p-wikibase-otherprojects p-wikibase-otherprojects-label

values: علاج جيني – Arabic

values:
interlanguage-link interwiki-bs
display: none;

values:
interlanguage-link interwiki-ca
display: none;

values:
interlanguage-link interwiki-cs
display: none;

values:
https://da.wikipedia.org/wiki/Genterapi
Genterapi – Danish
da
da
interlanguage-link-target

values:
interlanguage-link interwiki-da
display: none;

values:
interlanguage-link interwiki-de
display: none;

values:
interlanguage-link interwiki-et
display: none;

values:
interlanguage-link interwiki-eo
display: none;

values:
interlanguage-link interwiki-eu
display: none;

values: ژن‌درمانی – Persian

values:
interlanguage-link interwiki-fa
display: none;

values:
interlanguage-link interwiki-gl
display: none;

values: 유전자 치료 – Korean

values:
interlanguage-link interwiki-ko
display: none;

values: जीन चिकित्सा – Hindi

values: ריפוי גני – Hebrew

values:
interlanguage-link interwiki-he
display: none;

values:
interlanguage-link interwiki-jv
display: none;

values: ಜೀನ್(ವಂಶವಾಹಿ) ಚಿಕಿತ್ಸೆ – Kannada

values:
interlanguage-link interwiki-kn
display: none;

values:
interlanguage-link interwiki-ht
display: none;

values:
interlanguage-link interwiki-hu
display: none;

values: ജീൻ തെറാപ്പി – Malayalam

values:
interlanguage-link interwiki-ml
display: none;

values:
interlanguage-link interwiki-nl
display: none;

values:
interlanguage-link interwiki-ja
display: none;

values:
https://no.wikipedia.org/wiki/Genterapi
Genterapi – Norwegian
no
no
interlanguage-link-target

values:
interlanguage-link interwiki-no
display: none;

values:
interlanguage-link interwiki-pl
display: none;

values: Генотерапия – Russian

values:
interlanguage-link interwiki-simple
display: none;

values:
interlanguage-link interwiki-sl
display: none;

values: چارەسەرکردنی بۆھێلی – Central Kurdish

values:
interlanguage-link interwiki-ckb
display: none;

values:
interlanguage-link interwiki-fi
display: none;

values:
https://sv.wikipedia.org/wiki/Genterapi
Genterapi – Swedish
sv
sv
interlanguage-link-target

values:
interlanguage-link interwiki-sv
display: none;

values: மரபணு சிகிச்சை – Tamil

values:
interlanguage-link interwiki-ta
display: none;

values: జన్యు చికిత్స – Telugu

values:
interlanguage-link interwiki-te
display: none;

values: ยีนบำบัด – Thai

values: Генотерапія – Ukrainian

values:
interlanguage-link interwiki-uk
display: none;

values: وراثی معالجہ – Urdu

values: mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Gene_therapy rootpage-Gene_therapy skin-vector action-view